+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sodium Dependent Glucose Co Transporter 2"

From
From
From
From
From
From
From
Canada Diabetes Market Report and Forecast 2025-2034 - Product Thumbnail Image

Canada Diabetes Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 250 Pages
  • Canada
From
Type 2 Diabetes Pipeline Analysis Report - Product Thumbnail Image

Type 2 Diabetes Pipeline Analysis Report

  • Report
  • August 2024
  • 150 Pages
  • Global
From
From
Non-insulin Diabetes Therapeutics Market 2024-2028 - Product Thumbnail Image

Non-insulin Diabetes Therapeutics Market 2024-2028

  • Report
  • August 2024
  • 178 Pages
  • Global
From
Type 2 Diabetes Market 2025-2029 - Product Thumbnail Image

Type 2 Diabetes Market 2025-2029

  • Report
  • February 2025
  • 221 Pages
  • Global
From
Anti-Diabetic Drug Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Anti-Diabetic Drug Market - Forecasts from 2025 to 2030

  • Report
  • January 2025
  • 140 Pages
  • Global
From
From
From
From
Loading Indicator

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control. The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more